Protocol Ledger

NCT06824168 · Phase II · RECRUITING

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Interventional Phase II clinical trial protocol NCT06824168 sponsored by Daiichi Sankyo in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-18 Enrollment: 130 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06824168
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06824168
Protocol FieldVerified Registry Value
NCT IdentifierNCT06824168
Consolidated Lead SponsorDaiichi Sankyo
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment130 participants (ESTIMATED)
Registered Start Date2025-07-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI